The thymus and myasthenia gravis

Chest Surgery Clinics of North America

Volumn 11, Issue 2, 2001, Pages 311-327

  Ragheb, S ^a   Lisak, R P ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR;

COMORBIDITY; DISEASE ASSOCIATION; HUMAN; IMMUNE RESPONSE; LYMPHOID ORGAN; MYASTHENIA GRAVIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; THYMUS; THYMUS DISEASE;

AUTOANTIGENS; B-LYMPHOCYTES; HUMANS; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC; T-LYMPHOCYTES; THYMUS GLAND;

EID: 0034995359     PISSN: 10523359     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (161)

1. Muscle striational antibodies in myasthenia gravis: Diagnostic and functional significance
2. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin
3. The thymus in myasthenia gravis: Evidence for altered cell populations
4. Cellular immune response to acetylcholine receptor-rich fraction in patients with myasthenia gravis
5. Immunological relationships between acetylcholine receptor and thymus: A possible significance in myasthenia gravis
6. Serum globulin in myasthenia gravis: Inhibition of α-bungarotoxin binding to acetylcholine receptors
7. Acetylcholine receptor antibodies in myasthenia gravis
8. Cytokines: Coordinators of immune and inflammatory responses
9. Interferon γ (IFN-γ) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice
10. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis
11. The CD40 antigen and its ligand
12. Tumour necrosis factor-alpha (TNF-α): The good, the bad and potentially very effective
13. Mapping the main immunogenic region and toxin binding site of the nicotinic acetylcholine receptor
14. Myasthenia gravis: A serum factor blocking acetylcholine receptors of the human neuromuscular junction
15. Tumors of the thymus and thymic region. I. Clinicopathological studies on thymomas
16. Evaluation of T cell subsets in myasthenia gravis using anti-T cell monoclonal antibodies
17. Is CTLA-4 a master switch for peripheral T cell tolerance?
18. A severe combined immunodeficiency mutation in the mouse
19. In vitro synthesis of antibodies to acetylcholine receptor by Epstein-Barr virus-stimulated B-lymphocytes derived from patients with myasthenia gravis
20. Interleukin-12 alters the isotype-restricted antibody response of mice to hen egg-white lysozyme
21. The value of thymectomy in myasthenia gravis: A computer-assisted matched study
22. The pathology of the thymus gland in myasthenia gravis
23. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis
24. Monoclonal antibodies as probes of acetylcholine receptor structure. II. Binding to native receptor
25. Altered cell populations in thymuses from myasthenia gravis patients
26. Regulation of lymphocyte survival by the BCL-2 gene family
27. Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire
28. Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis
29. Actuarial analysis of the occurrence of remissions following thymectomy for myasthenia gravis in 400 patients
30. Increased thymocyte differentiation in myasthenia gravis: A dual color immunofluorescence phenotypical analysis
31. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: Ultrastructural and light microscopic localization and electrophysiological correlations
32. Thymic epithelial cell contains acetylcholine receptor
33. Neuromuscular junction in myasthenia gravis: Decreased acetylcholine receptors
34. Diverse Fabs specific for acetylcholine receptor epitopes from a myasthenia gravis thymus combinatorial library
35. Analysis of the human thymic perivascular space during aging
36. Immune regulation by CD40 and its ligand GP39
37. Increase in differentiated type of T lineage cells in the myasthenic thymus: Two color fluorocytometric analysis
38. Specific activation of lymphocytes against acetylcholine receptor in the thymus in myasthenia gravis
39. Acetylcholine receptor antibody-producing cells in thymus and lymph nodes in myasthenia gravis
40. Antibody to acetylcholine receptor in myasthenia gravis: Production by lymphocytes from thymus or thymoma
41. Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo
42. Pathogenetic significance of fetal acetylcholine receptors on thymic myoid cells in myasthenia gravis
43. Myasthenia gravis and the thymus
44. Anti-acetylcholine receptor antibodies directed against the α bungarotoxin binding site induce a unique form of experimental myasthenia
45. Human anti-nicotinic acetylcholine receptor recombinant Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies
46. Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review): Report of The Quality Standards Subcommittee of The American Academy of Neurology
47. Abnormal T-cell expansion and V-gene usage in myasthenia gravis patients
48. Immunological evidence for a change in subunits of the acetylcholine receptor in developing and denervated rat muscle
49. Individual germinal centers of myasthenia gravis human thymuses contain polyclonal activated B cells that express all the Vh and Vk families
50. Elimination of self-reactive B lymphocytes proceeds in two stages: Arrested development and cell death
51. Anti-acetylcholine receptor antibody specificities in serum and in thymic cell culture supernatants from myasthenia gravis patients
52. Early-onset myasthenia gravis: A recurring T-cell epitope in the adult-specific acetylcholine receptor epsilon subunit presented by the susceptibility allele HLA-DR52a
53. Potent immunostimulatory dendritic cells can be cultured in bulk from progenitors in normal infant and adult myasthenic human thymus
54. Myasthenia gravis: Stimulation of anti-receptor autoantibodies by autoreactive T cell lines
55. Autoimmune human T lymphocytes specific for acetylcholine receptor
56. Human T-helper lymphocytes in myasthenia gravis recognize the nicotinic receptor α subunit
57. Dinucleotide repeat expansion in the CTLA-4 gene leads to T cell hyper-reactivity via the CD28 pathway in myasthenia gravis
58. Genetic association of CTLA-4 to myasthenia gravis with thymoma
59. Tumour necrosis factor-α polymorphism and secretion in myasthenia gravis
60. Increased levels of circulating acetylcholine receptor (AChR)-reactive IL-10-secreting cells are characteristic for myasthenia gravis (MG)
61. Thymic muscle cells bear acetylcholine receptors: Possible relation to myasthenia gravis
62. + epitope sequences of the acetylcholine receptor
63. Reactivity of T cells from seronegative patients with myasthenia gravis to T cell epitopes of the human acetylcholine receptor
64. Pathogenesis of myasthenia gravis: Acetylcholine receptor-related antigenic determinants in tumor-free thymuses and thymic epithelial tumors
65. The molecular genetics of the T-cell antigen receptor and T-cell antigen recognition
66. Thymic B cells from myasthenia gravis patients are activated B cells: Phenotypic and functional analysis
67. Comparative immunoglobulin synthesis by blood lymphocytes in myasthenics and normals
68. Polyclonal B-cell activity in myasthenia gravis
69. Pokeweed mitogen-induced immunoglobulin secretory responses of thymic B cells in myasthenia gravis: Selective secretion of IgG versus IgM cannot be explained by helper functions of thymic T cells
70. Thymic B-cell activation in myasthenia gravis
71. In vitro T-cell dependent B-cell activity in myasthenia gravis
72. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part I. Relation to clinical parameters in 250 patients
73. Antibody to acetylcholine receptor in myasthenia gravis: Prevalence, clinical correlates and diagnostic value
74. In vitro synthesis of antibodies to acetylcholine receptor by peripheral blood cells: Role of suppressor T-cells in normal subjects
75. Suppressor T cells in myasthenia gravis and antibodies to acetylcholine receptor
76. In vitro synthesis of antibodies to acetylcholine receptor by peripheral blood mononuclear cells of patients with myasthenia gravis
77. Antibodies to acetylcholine receptor and tetanus toxoid: In vitro synthesis by thymic lymphocytes
78. In vitro synthesis of IgG and antibodies to AChR by peripheral and thymic lymphocytes
79. Mitogen and muscle extract induced in vitro proliferative responses in myasthenia gravis, dermatomyositis, and polymyositis
80. Thymic and peripheral blood T- and B-cell levels in myasthenia gravis
81. Thymic lymphocyte subpopulations in myasthenia gravis
82. Recombinant 25-kDa CD23 and interleukin 1α promote the survival of germinal center B cells: Evidence for bifurcation in the development of centrocytes rescued from apoptosis
83. Germinal center cells express bcl-2 protein after activation by signals which prevent their entry into apoptosis
84. Surface phenotypes of lymphoid cells altered in the human myasthenic thymus
85. Acetylcholine receptor expression in human extraocular muscles and their susceptibility to myasthenia gravis
86. Deletion of autoreactive B cells
87. From basic immunobiology to the upcoming WHO-classification of tumors of the thymus: The second conference on biological and clinical aspects of thymic epithelial tumors and related recent developments
88. The SCID-hu mouse: Murine model for the analysis of human hematolymphoid differentiation and function
89. T cells from normal and myasthenic individuals recognize the human acetylcholine receptor: Heterogeneity of antigenic sites on the α-subunit
90. The thymus in myasthenia gravis: Isolation of T lymphocyte lines specific for the nicotinic acetylcholine receptor from the thymuses of myasthenic patients
91. Interleukin-12 acts as an adjuvant for humoral immunity through interferon-γ-dependent and -independent mechanisms
92. Peripheral T cell tolerance
93. Molecular distinction between fetal and adult forms of muscle acetylcholine receptor
94. IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease
95. + cells of myasthenia gravis patients and healthy subjects
96. The structure and function of CD26 in the T-cell immune response
97. Transfer of a functional human immune system to mice with severe combined immunodeficiency
98. Expression of CD23 in the germinal center of thymus from myasthenia gravis patients
99. Adult thymus expresses an embryonic nicotinic acetylcholine receptor-like protein
100. Thymus cells in myasthenia gravis selectively enhance production of anti acetylcholine receptor antibody in autologous blood lymphocytes
101. Prognostic factors for myasthenia gravis treated by thymectomy: Review of 61 cases
102. Negative selection of lymphocytes
103. Cytokines induce the development of functionally heterogeneous T helper cell subsets
104. Upregulation of bcl-2 in the myasthenic thymus
105. Autoimmune T cell recognition in myasthenia gravis on the extracellular part of the α-subunit
106. T cell-dependent B cell activation
107. Autoimmune response to acetylcholine receptors
108. Lymphocyte responses and cytokines
109. IL-12 up-regulates CD40 ligand (CD154) expression on human T cells
110. Direct evidence for thymic function in adult humans
111. + T cell response to the human acetylcholine receptor α subunit in myasthenia gravis: A study with synthetic peptides
112. Myasthenia gravis: T epitopes on the δ subunit of human muscle acetylcholine receptor
113. + T epitopes on the embryonic γ subunit of human muscle acetylcholine receptor
114. Cell-surface expression of lymphocyte activation markers in myasthenia gravis
115. Antigenic determinants on the epsilon and gamma subunits of the acetylcholine receptor induce T-cell proliferation in myasthenia gravis (MG)
116. Cytokine production in autoimmune myasthenia gravis (MG)
117. Phenotypic and functional abnormalities of B-cells in myasthenia gravis
118. The immunopathogenesis of acquired (autoimmune) myasthenia gravis
119. + T cells in myasthenia gravis
120. Cellular immunity in myasthenia gravis: Response to purified acetylcholine receptor and autologous thymocytes
121. Interactions between immunogenic peptides and MHC proteins
122. In vitro anti-acetylcholine receptor antibody synthesis by myasthenia gravis patient lymphocytes: Correlations with thymic histology and thymic epithelial cell interactions
123. Acetylcholine receptor-specific T-lymphocyte clones in the normal human immune repertoire: Target epitopes, HLA restriction, and membrane phenotypes
124. Experimental autoimmune myasthenia gravis may occur in the context of a polarized Th1- or Th2-type immune response in rats
125. Acetylcholine receptor antibody synthesis by thymic lymphocytes: Correlation with thymic histology
126. Acetylcholine receptors in human thymic myoid cells in situ: An immunohistological study
127. Transplantation of thymic autoimmune microenvironment to severe combined immunodeficiency mice: A new model of myasthenia gravis
128. Developmental regulation of nicotinic acetylcholine receptors
129. Lymphocyte proliferation is controlled by both iron availability and regulation of iron uptake pathways
130. B and T cell involvement in anti-acetylcholine receptor antibody formation in myasthenia gravis
131. Failure to down-regulate Bcl-2 protein in thymic germinal center B cells in myasthenia gravis
132. Interleukin-12 enhances clinical experimental autoimmune myasthenia gravis in susceptible but not resistant mice
133. TNFA and TNFB polymorphisms in myasthenia gravis
134. Monoclonal antibody analysis of blood T cell subsets in myasthenia gravis
135. Acetylcholine receptor reactive T lymphocytes from healthy subjects and myasthenia gravis patients
136. Myasthenic thymus and thymoma are selectively enriched in acetylcholine receptor-reactive T cells
137. Intrathymic and extrathymic clonal deletion of T cells
138. B lymphocytes in the thymus of patients with myasthenia gravis
139. Functional diversity of T lymphocytes due to secretion of different cytokine patterns
140. Acetylcholine receptor structure, function, and evolution
141. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
142. Localisation of the main immunogenic region of human muscle acetylcholine receptor to residues 67-76 of the α subunit
143. Monoclonal antibodies used to probe acetylcholine receptor structure: Localization of the main immunogenic region and detection of similarities between subunits
144. Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis: An Fab monoclonal antibody protects against antigenic modulation by human sera
145. Marked increase in CD44-highly positive cells in hyperplastic thymuses from patients with myasthenia gravis
146. The thymic myoid cells and myasthenia gravis
147. Reactivity of myasthenia gravis serum globulin with skeletal muscle and thymus demonstrated by immunofluorescence
148. Relevance of antibodies against the α-bungarotoxin binding site on the human acetylcholine receptor in myasthenia gravis
149. Direct binding of IL-12 to human and murine B lymphocytes
150. Positive selection of lymphocytes
151. Expression of acetylcholine receptor genes in human thymic epithelial cells
152. + cells
153. Th1 epitope repertoire on the alpha subunit of human muscle acetylcholine receptor in myasthenia gravis
154. + T cell repertoire on the epsilon subunit of muscle acetylcholine receptor in myasthenia gravis
155. Intrathymic pathogenesis of myasthenia gravis: Transient expression of acetylcholine receptors on thymus-derived muscle cells
156. Molecular evidence for the expression of nicotinic acetylcholine receptor α-chain in mouse thymus
157. Differential regulation of muscle acetylcholine receptor γ- and ε-subunit mRNAs
158. Abnormal T cell receptor V gene usage in myasthenia gravis: Prevalence and characterization of expanded T cell populations
159. Engraftment of myasthenia gravis thymocytes into severe combined immunodeficiency (SCID) mice
160. Acetylcholine receptor autoantibody secretion by thymocytes: Relationship to myasthenia gravis
161. Immunological heterogeneity of autoreactive T lymphocytes against the nicotinic acetylcholine receptor in myasthenic patients